Virpax Pharmaceuticals Future Growth
Future criteria checks 0/6
Virpax Pharmaceuticals is forecast to grow earnings and revenue by 47.8% and 73.1% per annum respectively while EPS is expected to grow by 52.8% per annum.
Key information
47.8%
Earnings growth rate
52.8%
EPS growth rate
Pharmaceuticals earnings growth | 22.9% |
Revenue growth rate | 73.1% |
Future return on equity | n/a |
Analyst coverage | Low |
Last updated | 16 Nov 2023 |
Earnings and Revenue Growth Forecasts
Date | Revenue | Earnings | Free Cash Flow | Cash from Op | Avg. No. Analysts |
---|---|---|---|---|---|
12/31/2026 | N/A | -26 | N/A | N/A | 1 |
12/31/2025 | N/A | -23 | N/A | N/A | 1 |
12/31/2024 | N/A | -17 | N/A | N/A | 1 |
12/31/2023 | N/A | -15 | -10 | -10 | N/A |
9/30/2023 | N/A | -14 | -8 | -8 | N/A |
6/30/2023 | N/A | -15 | -11 | -11 | N/A |
3/31/2023 | N/A | -18 | -14 | -14 | N/A |
12/31/2022 | N/A | -22 | -18 | -18 | N/A |
9/30/2022 | N/A | -23 | -21 | -21 | N/A |
6/30/2022 | N/A | -18 | -20 | -20 | N/A |
3/31/2022 | N/A | -15 | -18 | -18 | N/A |
12/31/2021 | N/A | -12 | -15 | -15 | N/A |
9/30/2021 | N/A | -9 | -10 | -10 | N/A |
6/30/2021 | N/A | -7 | -6 | -6 | N/A |
3/31/2021 | N/A | -6 | -4 | -4 | N/A |
12/31/2020 | N/A | -4 | -1 | -1 | N/A |
9/30/2020 | N/A | -4 | -2 | -2 | N/A |
6/30/2020 | N/A | -4 | -1 | -1 | N/A |
3/31/2020 | N/A | -3 | -1 | -1 | N/A |
12/31/2019 | N/A | -3 | -1 | -1 | N/A |
Analyst Future Growth Forecasts
Earnings vs Savings Rate: VRPX is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: VRPX is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: VRPX is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: VRPX is forecast to have no revenue next year.
High Growth Revenue: VRPX is forecast to have no revenue next year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: Insufficient data to determine if VRPX's Return on Equity is forecast to be high in 3 years time